News

Explore the latest dermatology trends for 2026, including innovative therapies for psoriasis, atopic dermatitis, and hair-loss advancements.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

In case you missed it, this week we had news on the commercial launch of cosibelimab-ipdl, dupilumab in pediatric AD, a phase 3 trial of lebrikizumab in nummular eczema, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

A Winter Clinical Hawaii poster determined that roflumilast cream 0.05% is well tolerated and effective for diverse patient populations with atopic dermatitis

Psoriasis impacts physical and emotional health, with hidden burdens like trauma and IPV affecting quality of life and care access.

Renata Block, DMSc, MMS, PA-C, explores how AI could transform dermatology with insights from Dr. GPT on integration, equity, and the future of patient care.

Sun Pharma has launched cosibelimab-ipdl for advanced cutaneous squamous cell carcinoma, offering new hope for patients with limited treatment options.

Almirall initiates a pivotal phase 3 trial for lebrikizumab, targeting nummular eczema and aiming to enhance treatment options for this challenging condition.

Heap discusses promising phase 3 results for zasocitinib, an oral TYK2 inhibitor, showcasing its efficacy and safety in psoriasis therapy.

Researchers explore CO₂ laser therapy's effectiveness for refractory HHD, revealing its potential to restore skin health and reduce inflammation.

Discover how auricular acupuncture could enhance facial aesthetics, offering non-invasive rejuvenation with rapid results and minimal downtime for wrinkle reduction.

Topical roflumilast 0.3% cream shows promise in reducing lesions and symptoms of mild hidradenitis suppurativa (HS), offering a well-tolerated treatment option.

Explore the complexities of managing hidradenitis suppurativa (HS) through real-world case studies moderated by Afsaneh Alavi, MD.

Experts discuss real-world applications of JAK inhibitors for alopecia areata, emphasizing patient selection, psychosocial impacts, and personalized treatment strategies.

The National Psoriasis Foundation (NPF) redefines psoriasis severity, emphasizing disease impact over extent, enhancing treatment access, and aligning clinical practice with patient needs.

This review of the latest dermatologic studies includes insights on the "fear of overfilling," sexual adverse events from oral finasteride, post-laser, fibronectin-based skin care regimens, and more.

The RWEAL study uncovers real-world management of chronic hand eczema (CHE), highlighting treatment gaps and the need for standardized assessment in clinical practice.

Connect Biopharma reveals innovative data on rademikibart's mechanism of action, highlighting its potential impact on atopic dermatitis and future clinical priorities.

Recludix Pharma has initiated clinical trials for REX-8756, a promising oral STAT6 inhibitor targeting inflammatory diseases, marking a significant milestone in treatment innovation.

Alpha Tau Medical advances Alpha DaRT for recurrent cutaneous squamous cell carcinoma (cSCC), offering a novel, localized treatment option with minimal toxicity.

Zasocitinib emerges as a highly selective and potent allosteric tyrosine kinase 2 (TYK2) inhibitor, showing promise for treating immune-mediated inflammatory diseases.

Dupilumab demonstrates significant efficacy and safety in treating severe atopic dermatitis in children aged 6 months to 5 years, improving quality of life.

New research confirms how skin tension line-oriented grafting enhances cosmetic outcomes in basal cell carcinoma surgery, improving aesthetics without compromising quality of life.

Oruka Therapeutics reveals promising interim results for ORKA-002 and launches the EVERLAST-B trial for ORKA-001, targeting chronic skin diseases.

Adelle Walker explores the future of aesthetics as personalized, holistic approaches and regenerative treatments, particularly in younger patients, reshape trends in 2026.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.